T-1249

HIV/AIDS-Related Uses

T-1249 is a second-generation peptide fusion inhibitor being studied in clinical trials. Specifically, T-1249 is being studied as a salvage therapy for patients who have failed enfuvirtide (T-20) therapy. T-1249 has shown unique potency against a broad range of HIV isolates in laboratory and animal studies.[1] [2]

Due to challenges with achieving the technical profile required of the current formulation of T-1249, Roche and Trimeris have decided to put its early stage clinical program on hold.[3]

Pharmacology

Dose-dependent decreases in HIV RNA were observed in a 14-day, dose-ranging pilot study. Patients received T-1249 monotherapy by subcutaneous injection at doses ranging from 6.25 mg/day to 50 mg/day. On day 14, the median change from baseline viral levels ranged from -0.10 (6.25 mg/day) to -1.40 (50 mg/day) log10 copies/ml. The plasma half-life and bioavailability supported once-daily dosing.[4]

Dose-dependent decreases in HIV RNA were also observed in a Phase I/II study in which 200 mg/day was the highest dose and corresponded to a median maximum change from baseline of -1.96 log10 copies/ml. The maximum CD4 cell increase was 70 cells/mm3 at a dose of 150 mg once daily.[5]

Preliminary results from an open-label salvage study of patients who were failing therapy with enfuvirtide showed an average viral load reduction of -1.12 log 10 at day 10. Those who had been on enfuvirtide for less than 48 weeks had a better response than those who had been on enfuvirtide for more than 48 weeks.[6]

Adverse Events/Toxicity

Clinical studies have reported two serious adverse events: hypersensitivity reaction (oral ulcers, maculopapular rash, fever) and grade 4 neutropenia. Injection site reactions were mild and reported in 40% of patients. No dose-limiting toxicities were identified. Headaches, fever, lymphadenopathy, candidiasis, and diarrhea have also been reported.[7] [8]

Clinical Trials

For information on clinical trials that involve T-1249, visit the ClinicalTrials.gov web site at http://www.clinicaltrials.gov. In the Search box, enter: T-1249 AND HIV Infections.

Dosing Information

Mode of Delivery: Subcutaneous injection.[9]

Manufacturer Information

T-1249
Hoffmann - La Roche Inc
340 Kingsland St
Nutley, NJ 07110-1199
(800) 526-6367

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

• Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET

• Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET

References

1. Conf Retroviruses Opportunistic Infect. - 8th; 2001. Abstract 14.

2. Conf Retroviruses Opportunistic Infect. - 10th; 2003. Abstract 14LB.

3. Hoffmann-LaRoche, Inc. - Available at: http://www.roche.com/med-corp-detail-2004?id=1107&media-language=e. Accessed 1/7/04.

4. Conf Retroviruses Opportunistic Infect. - 8th; 2001. Abstract 14.

5. Interscience Conf on Antimicrobial Agents and Chemotherapy - 42nd; 2002. Abstract H-1075.

6. Conf Retroviruses Opportunistic Infect. - 10th; 2003. Abstract 14LB.

7. Conf Retroviruses Opportunistic Infect. - 8th; 2001. Abstract 14.

8. Interscience Conf on Antimicrobial Agents and Chemotherapy - 42nd; 2002. Abstract H-1075.

9. Conf Retroviruses Opportunistic Infect. - 8th; 2001. Abstract 14.